Lilly to build $2.5 billion Germany plant as obesity drug demand soars

[ad_1]

DealsHealth

Reuters exclusively reported that Eli Lilly (LLY.N) will build its first plant in Germany in the western town of Alzey for 2.3 billion euros ($2.5 billion), the U.S. drugmaker said on Friday, as the sector scrambles to meet soaring demand for new diabetes and obesity therapies. 

Market Impact

As the sector scrambles to meet demand for new diabetes and obesity therapies, the investment, confirmed by Lilly on Nov 17, will contribute to meeting surging demand for weight-loss drug Mounjaro from 2027. Eli Lilly and Danish rival Novo Nordisk (NOVOb.CO) are leading a race to seize an estimated $100 billion future global market for anti-obesity treatments.   

Article Tags

Topics of Interest: DealsHealth

Type: Reuters Best

Sectors: Pharmaceuticals & HealthcareRetail & Consumer Goods

Regions: Europe

Countries: Germany

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

[ad_2]

Source link

Related articles

Study finds these 6 foods essential to reduce heart diseases

[ad_1] Cardiovascular disease is one of the leading causes of death in India. While many studies indicate a strong link between diet and heart problems, a new research suggests six main food groups, when added to your diet daily, and lower risk of cardiovascular disease. The study, published in the European Heart Journal, combined the […]

6 unexpected health benefits of walking

[ad_1] Walking for 30 minutes every day can improve your health in more ways than you might expect. Not only is walking a fantastic, low-impact form of cardiovascular exercise, it can significantly improve your mental and emotional health, and help with every wellness goal from stress to sleep. Not many people recognize walking as a […]

Leave a Reply

Your email address will not be published. Required fields are marked *